Year-end report 2026, January 1–September 30

July–September 2026

Net revenue was SEK 384.5 million (363.2), an increase of 5.9%, of which +4.7% was organic and +1.2% currency effects

Order intake amounted to SEK 362.9 million (349.2), an increase of 3.9%, of which +1.9% was organic and +2.0% currency effects

EBITA was SEK 45.4 million (56.4), a decrease of 19.4%

Operating profit (EBIT) was SEK 58.9 million (44.8)

Profit for the period was SEK 83.2 million (56.0) and adjusted profit for the period was SEK 10.1 million (19.0)

Operating cash flow was SEK 22.5 million (35.3), a decrease of 36.4%

January–September 2026

Net revenue was SEK 1,113.9 million (1,183.2), a decrease of 5.9%, of which -2.7% was organic
and -3.2% currency effects

Order intake amounted to SEK 1,182.9 million (1,156.4), an increase of 2.3%, of which +5.7% was organic and -3.4% currency effects

EBITA was SEK 132.7 million (193.0), a decrease of 31.2%

Operating profit (EBIT) was SEK 106.9 million (164.3)

Profit for the period was SEK 77.7 million (-1.2) and adjusted profit for the period was SEK 32.9 million (55.5)

Operating cash flow was SEK 107.2 million (88.7), an increase of 20.8%

The Board of Directors proposes that no dividend be paid in respect of the shortened transitional financial year January–September 2026

Comparative figures above for January–September 2026 refer to January–September 2025.

CEO’s comment

Return to organic growth

In the third quarter, ADDvise returned to organic growth. Net revenue increased by 5.9 percent compared with the corresponding quarter last year. In constant currency, net revenue increased organically by 4.7 percent. At the same time, order intake continued to develop positively and increased by 3.9 percent, corresponding to an increase of 1.9 percent organically in constant currency.

It is gratifying to see organic growth again after a weaker start to the year. The development during the quarter shows continued good demand for the Group’s products and services. In the quarter, sales of laboratory equipment and medical consumables were the main drivers of growth. For the period January–September, organic order intake increased by 5.7 percent.

EBITA amounted to SEK 45.4 million (56.4), corresponding to an EBITA margin of 11.8 percent (15.5). Profitability is not at the level we are aiming for. The lower margin is mainly due to a less favourable product mix and higher costs for freight and raw materials and, to some extent, sales and marketing. We believe that we can gradually pass on a large part of the increased freight and raw material costs to customers. We have a clear focus on improving profitability and are actively working on cost adjustments and operational improvements in our companies. Our decentralised model means that measures are taken close to each business and adapted to the specific conditions of the subsidiaries.

Cash flow from operating activities amounted to SEK 22.5 million (35.3) during the quarter. For the period January–September, the corresponding cash flow amounted to SEK 107.2 million, compared to SEK 88.7 million last year.

Net debt to EBITDA at the end of the period amounted to 4.1 times. During the year, we made significant payments amounting to SEK 166.9 million in contingent purchase considerations for previously completed acquisitions. Strengthening cash flow and reducing debt remains a high priority.

During the year, ADDvise gained a new owner through Amplex and became a business area within the Amplex Group. At the same time, our basic model remains unchanged. Our companies will continue to be run in a decentralised manner with great local responsibility and a focus on profitable growth, strong cash flows and long-term value creation. The third quarter also concludes the current financial year when ADDvise, in line with the rest of the Amplex Group, transitions to a non-calendar financial year with the period October–September.

As a result of the compulsory redemption procedure regarding the warrants, which were issued in connection with the rights issue in 2025, the related derivative liability was derecognised. This had a positive impact of SEK 51.7 million on net financial items for the quarter. This is a one-off accounting effect that does not affect cash flow.

We are exiting the period with improved revenue development and continued positive order intake. At the same time, we are not satisfied with profitability and have a clear task ahead of us. Our focus is therefore on continued organic growth, improved margins, stronger cash flow and reduced debt.

I would like to thank all our employees for your commitment and efforts. Together with the strong market positions in our companies, you create good conditions for ADDvise’s continued development. Through our joint work, we develop companies that with their products and services improve, save and extend people’s lives.

Staffan Torstensson, CEO

For further information, please contact:

Staffan Torstensson, CEO

+46 (0) 70-433 20 19

staffan.torstensson@addvisegroup.se

Johan Irwe, CFO

+46 (0) 73-731 26 11

johan.irwe@addvisegroup.se

ADDvise’s financial reports are available on ADDvise’s website, https://www.addvisegroup.com/investor-relations/financial-and-annual-reports/

The interim report is published in Swedish and English. The Swedish version represents the original.

About ADDvise

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.6 billion. Since 2026, ADDvise is a business area within the privately owned Swedish group Amplex AB. More information is available at www.addvisegroup.com.